Anxiety Disorders and Depression Treatment Market Analysis by Drugs (Beta Blockers, TeCAs, SNRIs, TCAs, SSRI, MAOIs, Anticonvulsants, Atypical Antipsychotics and Benzodiazepines) Pipeline (ALKS 5461, Brintellix and Brexpiprazole) Analysis, Regional Outlook, Competitive Strategies and Forecasts, 2014 to 2022
Global anxiety disorders and depression treatment market is expected to witness remarkable growth over the coming seven years due to rising incidences of depression and anxiety disorders coupled with growing geriatric population base. In addition, factors such as introduction of efficient products with less side effects and increasing demand for antidepressants used in treatment of panic disorders, phobias and obsessive compulsive disorder are expected to result in increased growth of this market over the forecast period.
For More Information on "Anxiety Disorders and Depression Treatment Market
Research
Reports"
visit
-
http://www.grandviewresearch.com/industry-analysis/anxiety-disorders-anddepression-treatment-market
The global anxiety disorders and depression treatment market is categorized on the basis of drugs and pipeline analysis. By drugs, the market is divided into beta blockers, TeCAs (Tetracyclic Antidepressants), SNRIs (Serotonin Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), SSRI (Selective Serotonin Reuptake Inhibitors), MAOIs (Monoamine Oxidase Inhibitors), anticonvulsants, atypical antipsychotics and benzodiazepines. The SNRIs market segment is expected to witness fastest growth owing to higher efficiency rate in treatment of generalized anxiety disorders. By pipeline analysis, the market is divided into ALKS 5461, Brintellix and Brexpiprazole.
Increasing clinical trials and anticipated commercialization of pipeline products are expected to propel the growth of antidepressants drugs market over the forecast period. Regionally, as of 2014, North America witnessed highest share owing to increasing incidence of depression, availability of multi brand formulations and favourable government policies. European region is expected to witness rapid growth due to growing geriatric population base and increased usage of antidepressants in this region. Rising disposable income, awareness about antidepressants and prevalence of anxiety disorders are expected to result in fastest market growth in Asia pacific region. Also, Latin America region is anticipated to register steady growth owing to revamped healthcare facilities in this region. The market players operating in global anxiety disorders and depression treatment market are Johnson & Johnson, Merck & Co., Sanofi Aventis, Eli Lilly & Co., AstraZeneca plc, Pfizer Inc., GlaxoSmithKline plc, Forest Laboratories Inc. and H. Lundbeck A/S. The companies are adopting competitive strategies such as new product development and modification of distribution channels to increase their market penetration.
For example, Forest Laboratories launched a drug namely Vilazodone in June 2014, which provides high tolerability, efficiency and safety in treatment of GAD (Generalized Anxiety Disorder). Also, in 2013, Eli Lilly and Co. introduced Duloxetine, a SNRI for the treatment of depressive disorder, generalized anxiety disorder and post traumatic stress disorder.
Request TOC of “Anxiety Disorders and Depression Treatment Market Research Reports" visit - http://www.grandviewresearch.com/industryanalysis/anxiety-disorders-and-depression-treatment-market/request-toc
About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact: Sherry James Corporate Sales Specialist, U.S.A. Grand View Research, Inc. United States Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@grandviewresearch.com Website: Grand View Research Blog Site: http://www.divog.org/